Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLiabilities from Discontinued OperationsLong-Term Deferred TaxLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsNon-Current ReceivablesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetReceivables - OtherReceivables RefundsShares OutstandingShares Outstanding
Ratios

Sanofi (SNY) Shares Outstanding (2017 - 2025)

Sanofi's Shares Outstanding history spans 9 years, with the latest figure at $1.4 billion for Q4 2025.

  • On a quarterly basis, Shares Outstanding rose 5.16% to $1.4 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 billion, a 5.16% increase, with the full-year FY2025 number at $1.4 billion, up 5.16% from a year prior.
  • Shares Outstanding hit $1.4 billion in Q4 2025 for Sanofi, up from $1.3 billion in the prior quarter.
  • Over the last five years, Shares Outstanding for SNY hit a ceiling of $1.4 billion in Q4 2021 and a floor of $1.3 billion in Q4 2022.
  • Historically, Shares Outstanding has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
  • Biggest five-year swings in Shares Outstanding: decreased 11.01% in 2022 and later increased 5.79% in 2023.
  • Tracing SNY's Shares Outstanding over 5 years: stood at $1.4 billion in 2021, then fell by 11.01% to $1.3 billion in 2022, then grew by 5.79% to $1.4 billion in 2023, then dropped by 0.81% to $1.3 billion in 2024, then increased by 5.16% to $1.4 billion in 2025.
  • Business Quant data shows Shares Outstanding for SNY at $1.4 billion in Q4 2025, $1.3 billion in Q4 2024, and $1.4 billion in Q4 2023.